tetracycline and Hyperparathyroidism

Topics: Bone and Bones; Calcifediol; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Osteoclasts; Osteomalacia; Tetracycline; Uremia

Topics: Adolescent; Adult; Aged; Biopsy; Bone and Bones; Bone Development; Bone Diseases, Metabolic; Bone Resorption; Child; Child, Preschool; Female; Humans; Hyperparathyroidism; Hyperthyroidism; Infant; Male; Middle Aged; Osteogenesis; Osteoporosis; Tetracycline

Topics: Absorptiometry, Photon; Adult; Aged; Aging; Bone Diseases; Bone Resorption; Calcium; Child; Estrogens; Female; Humans; Hydroxyproline; Hyperparathyroidism; Joint Diseases; Male; Microradiography; Middle Aged; Osteitis Deformans; Osteomalacia; Osteoporosis; Parathyroid Glands; Physical Therapy Modalities; Spine; Tetracycline

In this article, an explanation and definition of basic terms used in metabolic bone disease are presented, with a review of histomorphometric findings in osteoporosis, osteomalacia, Paget's disease, and hyperparathyroidism. An appropriate bone biopsy protocol for diagnostic purposes is also presented.

Topics: Biopsy; Bone and Bones; Bone Diseases, Metabolic; Bone Marrow; Humans; Hyperparathyroidism; Microscopy, Fluorescence; Minerals; Osteitis Deformans; Osteoblasts; Osteoclasts; Osteomalacia; Osteoporosis; Tetracycline

Bone biopsies of 23 subjects suffering from primary hyperparathyroidism, which was proven by the demonstration of parathyroid pathology during neck surgery, were studied by morphometric analysis and short interval sequential tetracycline labelling and compared with those of 13 patients without metabolic bone disease. In 19 of these patients, abnormalities were found in the trabecular volume, resorption surface, formation surface, or in various combinations. However, no constant pattern of bone changes was observed. In 4 patients, the bone morphometric parameters were normal. The bone apposition rate, on the other hand, was elevated in all 23 subjects. The rate was re-evaluated in 4 patients 6 wk to 3 mo following successful parathyroid surgery. It fell back within the control range. These findings confirm the observation in experimental animals that parathyroid hormone stimulates bone apposition in vivo and give support to the rationale of using this hormone in the treatment of osteoporosis.

Topics: Adolescent; Adult; Aged; Bone and Bones; Bone Development; Female; Humans; Hyperparathyroidism; Kinetics; Male; Middle Aged; Tetracycline

Quantitative histomorphometric analyses of iliac crest biopsy specimens were performed after tetracycline double-labeling in 41 normal individuals, 20 hyper- and 10 hypothyroid patients, 18 patients with primary hyperparathyroidism, 20 epileptic patients receiving long-term anticonvulsant therapy, and 17 patients after jejunoileal bypass for morbid obesity. The mineralization lag time in trabecular bone or the period of time between apposition and subsequent mineralization of osteoid was calculated from the bone formation rate at BMU level (Basic Multicellular Unit) and the mean width of osteoid seams. The mineralization lag time was 8-52 days (median 21 days) in normal individuals and showed no variation with sex or age. The mineralization lag time was shortened in hyperthyroidism, normal in anticonvulsant bone disease and in primary hyperparathyroidism, and markedly prolonged in hypothyroidism and following jejunoileal bypass. Among all individuals an inverse hyperbolic relation (r = 0.94, p less than 0.001) was found between the mineralization lag time and the average cellular activity of the osteoblasts.

Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Diseases; Female; Humans; Hyperparathyroidism; Hyperthyroidism; Hypothyroidism; Ileum; Ilium; Male; Middle Aged; Minerals; Obesity; Osteoblasts; Osteomalacia; Phenytoin; Postoperative Complications; Tetracycline; Time Factors

Increased bone, resorption previously found in hyperthyroidism might be caused by a direct stimulating effect of thyroid hormone(s) on bone cells or by an increased sensitivity to circulating parathyroid hormone. In order to disclose qualitative differences in the response of bone resorbing cells to excess parathyroid hormone and excess thyroid hormone(s), histomorphometric analysis of iliac crest biopsies was performed in 25 hyperparathyroid and 40 hyperthyroid patients after tetracycline double-labelling. The main target cells for parathyroid and thyroid hormones were different. Parathyroid hormone stimulated osteocytic osteolysis and increased osteoclastic resorption surfaces equally in trabecular and cortical bone. The osteoclastic resorption was inactive. Thyroid hormone(s) had no effect on osteocytes but increased the osteoclastic resorption surfaces in trabecular and cortical bone, with a pronounced preponderance in cortical bone. The osteoclastic resorption was active and followed by a significant loss of both cortical and trabecular bone. The findings support the assumption that increased bone resorption in hyperthyroidism is caused by a direct stimulating effect of thyroid hormone(s).

Topics: Adult; Aged; Bone and Bones; Bone Resorption; Calcium; Female; Humans; Hyperparathyroidism; Hyperthyroidism; Ilium; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Tetracycline; Thyroid Hormones

Twenty-five patients with end-stage renal disease, nine of whom were receiving pharmacologic doses of vitamin D, and seventeen patients with primary hyperparathyroidism underwent bone biopsy following a three-day course of tetracycline administration. The mean width of the fluorescent tetracycline bands were significantly greater in the bones of patients with uremia than in those with primary hyperparathyroidism. This difference was due to wide labels present in the patients with uremia who had not been treated with vitamin D, as no differences existed in mean label widths of patients with uremia who had received this compound and the patients with primary hyperparathyroidism. Comparison of the maximum label widths distinguished not only primary hyperparathyroid patients from those with uremia, but uremic patients who had recieved vitamin D from those who had not been so treated. Quantitative microscopy of standard, nonfluorescent histologic features failed to make this latter distinction. These data are consistent with the presence of a wide zone of instantaneously fluorescing material in uremic bone following tetracycline administration, which does not relate to bone apposition occurring during antibiotic administration. This phenomenon probably represents a delay in mineral maturation which is normalized by vitamin D. Furthermore, it is apparent that the use of a continuously administered (single) tetracycline label will result in an overestimation of bone formation rates, particularly in osteomalacic states.

Topics: Adult; Biopsy; Bone and Bones; Female; Fluorescence; Humans; Hyperparathyroidism; Male; Middle Aged; Tetracycline; Uremia; Vitamin D

Topics: Adenoma; Adult; Aged; Biopsy; Bone and Bones; Bone Development; Bone Resorption; Child, Preschool; Female; Humans; Hyperparathyroidism; Male; Middle Aged; Parathyroid Hormone; Parathyroid Neoplasms; Ribs; Tetracycline

Topics: Adolescent; Adult; Biopsy; Bone Regeneration; Bone Resorption; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Haversian System; Humans; Hyperparathyroidism; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Osteoclasts; Renal Dialysis; Tetracycline

Topics: Ascorbic Acid; Bone and Bones; Calcification, Physiologic; Calcium Isotopes; Calcium, Dietary; Femur; Hyperparathyroidism; Metabolism; Mice; Oxytetracycline; Pharmacology; Rats; Research; Strontium; Strontium Isotopes; Tetracycline; Tibia; Toxicology

Topics: Anti-Bacterial Agents; Bone and Bones; Fluorescence; Humans; Hyperparathyroidism; Radiography; Research; Tetracycline